Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

22,209,203 25,554,214

Property and equipment 192,582 201,103

Intellectual property 5,006,297 5,026,540

-------------------------------------------------------------------------

27,408,082 30,781,857

-------------------------------------------------------------------------

-------------------------------------------------------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY

Current

Accounts payable and accrued liabilities 2,752,100 2,821,227

-------------------------------------------------------------------------

Shareholders' equity

Share capital

Authorized: unlimited number of common shares

Issued: 41,180,748 (December 31, 2007 -

41,180,748) 92,759,665 92,759,665

Warrants 5,346,260 5,346,260

Contributed surplus (note 3) 10,396,555 10,376,962

Deficit (note 4) (83,846,498) (80,522,257)

-------------------------------------------------------------------------

24,655,982 27,960,630

-------------------------------------------------------------------------

27,408,082 30,781,857

-------------------------------------------------------------------------

-------------------------------------------------------------------------

See accompanying notes

Oncolytics Biotech Inc.

CONSDOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

(unaudited)

Cumulative


'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 A study has been ... the Formula 1 track could help to tackle the problem ... (MAT), Stowhealth (a GP surgery based in Stowmarket) and academics ... Simplyhealth. Telemetry technology, which is inspired by equipment ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Six Years Recognizes Breakthrough ... Form of Heart Disease, ABBOTT PARK, Ill., Oct. ... Chicago Innovation Award for its XIENCE V(TM),Everolimus Eluting Coronary ... clinical data, the next-generation drug eluting stent,represents a significant ...
... CAMBRIDGE, Mass., Oct. 28 Peptimmune, Inc., a privately,held biotechnology ... provide an update on the Company,s current phase Ib clinical,trial ... 1. BIO Investor Forum 2008. The presentation will ... at 3:15 p.m. in the Pacific Room at the Palace ...
... DIEGO, Oct. 28 Volcano Corporation,(Nasdaq: VOLC ), ... for the diagnosis and treatment of coronary and peripheral ... results for the,third quarter and first nine months of ... hold a conference call to discuss its financial,results and ...
Cached Biology Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award 2Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award 3Peptimmune Presentations at Upcoming Events 2Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2
(Date:4/23/2014)... in their mid-thirties and forties, face a devastating ... two decades. "Mutant" protein clusters, long blamed for ... the primary focus of therapies in development by ... Prof. Gerardo Lederkremer and Dr. Julia Leitman of ... Immunology, in collaboration with Prof. Ulrich Hartl of ...
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23 2014) ... human neural stem cells (hNSCs) into the brains ... differentiation after 22 and 24 months found that ... months and did not cause tumors. , The ... of Cell Transplantation but is currently ...
(Date:4/23/2014)... likelihood of an accurate group decision increases with the ... a collective faces a variety of factors as ... researchers report that smaller groups actually tend to make ... focused on only certain pieces of information. , The ... about collective intelligence, or the "wisdom of crowds," wherein ...
Breaking Biology News(10 mins):On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... common, but few studies of lung nodule identification and ... from Kaiser Permanente Southern California identified 7,112 patients who ... within the electronic medical record. Their study ... Association for the Study of Lung Cancer,s (IASLC) ...
... WORCESTER, Mass. A new genetic mutation that causes ... also known as Lou Gehrig,s Disease, has been identified ... the University of Massachusetts Medical School (UMMS). Mutations to ... growth and development of nerve cell axons, is estimated ...
... new study by University of North Carolina School of Medicine ... risk for autism spectrum disorders (ASD) at 12 months received ... In addition, 85 percent of the children found to be ... Year Inventory (FYI), a 63-item questionnaire filled out by their ...
Cached Biology News:UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3Questionnaire completed by parents may help identify 1-year-olds at risk for autism 2
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
prototype Nco I...
Biology Products: